The Personal Care Edition
Female HRT: Benefits, Risks, and a More Personal Decision
Your symptoms. Your history. A more personal conversation.
Begin reading
The short version
Menopausal hormone therapy can be a highly effective treatment for bothersome hot flashes and night sweats, but it is not the right choice for every woman. It also prevents bone loss and can help menopause-related vaginal symptoms; the appropriate product depends on which problem is being treated. The Menopause Society: Hormone therapy position statement (2022)
At Infinity Functional Performance, our starting question is simple: what is interfering with your life? Bring that answer to a conversation about benefits, alternatives, and your personal health history rather than trying to select a hormone from a social-media headline.
- Timing matters: For otherwise healthy women younger than 60 or within 10 years of menopause, without contraindications, the benefit-risk balance is often favorable for bothersome symptoms. The Menopause Society: Hormone therapy position statement (2022)
- Route matters: A skin patch and a low-dose vaginal product do different jobs; they are not interchangeable. The Menopause Society: Hormone therapy position statement (2022)
- History matters: Prior clots, certain cancers, liver disease, unexplained bleeding, and cardiovascular events can change or rule out systemic treatment. The Menopause Society: Hormone therapy position statement (2022)
First, choose the problem you want to solve
Imagine two women asking about “HRT.” One is waking repeatedly with drenching night sweats; the other sleeps well but has vaginal dryness and pain with sex. Both deserve care, but their best treatment conversations may be quite different.
Systemic therapy circulates through the body and is used for symptoms such as hot flashes and night sweats. When vaginal or urinary symptoms are the only concern, low-dose vaginal estrogen is often preferred because it acts mainly in those tissues with minimal systemic absorption. The Menopause Society: Hormone therapy position statement (2022)
That distinction can prevent unnecessary treatment escalation. Tell your provider what happens, how often, how long it has been happening, and what you have already tried; a short symptom diary can make the visit more useful.
Estrogen, progesterone, and the uterus
Systemic estrogen can stimulate the uterine lining, so a woman who still has a uterus generally needs an appropriate progestogen or another approved endometrial-protection regimen. Estrogen alone is often an option after hysterectomy, although the full clinical history still matters. The Menopause Society: Hormone therapy position statement (2022)
Recommended low-dose vaginal estrogen usually does not require added progestogen, but long-term randomized endometrial-safety data are limited. Any bleeding after menopause deserves evaluation rather than an assumption that it is simply a hormone side effect. The Menopause Society: Hormone therapy position statement (2022)
Do not borrow another person's prescription or assume that a product's dose can be compared directly across creams, rings, tablets, and patches. Ask which formulation is being proposed, why it matches your goal, and how you will use it.
What treatment can and cannot promise
The strongest reasons to consider menopausal hormone therapy are symptom relief and, for appropriate patients, prevention of bone loss. Sleep may improve when treatment reduces bothersome nighttime hot flashes; that is different from saying hormones fix every cause of insomnia. The Menopause Society: Hormone therapy position statement (2022)
Hormone therapy is not recommended as a general strategy to prevent heart disease or dementia. Neither a possible biological mechanism nor an observational association makes it a proven longevity treatment. The Menopause Society: Hormone therapy position statement (2022)
Testosterone is a separate discussion: its strongest evidence in women is for postmenopausal hypoactive sexual desire disorder, not a general “energy, muscle, and brain” add-on. Global consensus on testosterone therapy for women (2019)
The goal is not to restore a younger version of a laboratory report. The goal is a meaningful improvement that is worth the risks for you.
Risk is specific, not all-or-nothing
Breast-cancer risk varies with regimen, duration, and patient characteristics; results from estrogen alone cannot simply be transferred to combined therapy. A label such as “bioidentical” does not establish that a product has no cancer risk. The Menopause Society: Hormone therapy position statement (2022)
Transdermal estrogen may have a lower clot-risk profile than oral estrogen, but head-to-head randomized evidence is limited. “Potentially lower risk” is not the same as “zero risk,” especially for someone with a prior clot or other contraindication. The Menopause Society: Hormone therapy position statement (2022)
Systemic hormone therapy is generally not advised for breast-cancer survivors. For persistent vaginal symptoms after nonhormonal measures, low-dose vaginal treatment may sometimes be considered with the oncology team; extra caution applies with aromatase-inhibitor treatment. The Menopause Society: Hormone therapy position statement (2022)
What changed in the FDA warnings?
In February 2026, the FDA approved label changes for six menopausal hormone products, removing cardiovascular disease, breast cancer, and probable dementia statements from their boxed warnings. The announcement covered an initial group of products, not a declaration that all hormone therapy is risk-free. FDA: Approved menopausal hormone therapy label changes (February 2026)
Use the current prescribing information for the exact medication under discussion. The practical lesson is to replace blanket fear with a more specific benefits-and-risks conversation, not to replace caution with blanket reassurance.
“Bioidentical” does not mean “compounded”
Bioidentical describes a hormone's molecular structure, and FDA-approved estradiol and micronized progesterone products are available. Custom-compounded hormones are a different regulatory category and are not FDA-approved finished drugs. The Menopause Society: Hormone therapy position statement (2022) FDA: Compounding and the FDA, questions and answers
Compounding may meet a specific need when an appropriate approved option cannot be used, but it is not automatically safer or more precisely individualized. Routine saliva or urine testing to set menopausal hormone doses is not recommended. The Menopause Society: Hormone therapy position statement (2022)
Your decision at a glance
| Question | Useful distinction |
|---|---|
| Hot flashes and night sweats? | Discuss systemic treatment and nonhormonal alternatives. The Menopause Society: Hormone therapy position statement (2022) |
| Vaginal symptoms only? | Local low-dose therapy may fit better than systemic treatment. The Menopause Society: Hormone therapy position statement (2022) |
| Still have a uterus? | Systemic estrogen generally needs endometrial protection. The Menopause Society: Hormone therapy position statement (2022) |
| Prior clot, cancer, stroke, or unexplained bleeding? | Review before treatment; systemic therapy may be contraindicated. The Menopause Society: Hormone therapy position statement (2022) |
| Reaching age 65 while doing well? | There is no universal automatic stop date; reassess individually. The Menopause Society: Hormone therapy position statement (2022) |
Questions worth bringing to your visit
Ask which symptom the prescription is meant to improve, what nonhormonal choices are available, what would make treatment unsafe, and when you will reassess. Bring your medication list, cancer and clot history, any bleeding history, and your most important treatment goal.
Does every woman need a large hormone panel?
No. Routine hormone measurements are often unnecessary for menopausal hormone dosing; testing should answer a specific clinical question rather than satisfy a standard shopping list. The Menopause Society: Hormone therapy position statement (2022)
Must I stop after a fixed number of years?
Not automatically. Continued use may be appropriate for a documented reason with periodic review of benefits, risks, and alternatives. The Menopause Society: Hormone therapy position statement (2022)
Is menopause itself a disease?
No. It is a normal life stage, and symptoms can still deserve effective treatment without turning every woman into a patient who needs hormones. FDA: Approved menopausal hormone therapy label changes (February 2026)
The honest bottom line
Menopausal hormone therapy can offer meaningful relief, but the right choice depends on symptoms, timing, uterus status, and medical history. Choose an individualized discussion over either “everyone needs it” or “no one should use it.” The Menopause Society: Hormone therapy position statement (2022)
Your next step
Bring your questions, medication list, and relevant results to a conversation with licensed medical providers. Infinity Functional Performance can help you explore whether an individualized evaluation is appropriate; no particular test, medication, or result is promised.
Visit ifp.life, call 972-619-5350, or email info@ifp.life to learn about becoming a patient.
Educational content only. This article is not a diagnosis, prescription, or substitute for individual medical advice. Do not start, stop, or adjust treatment based on a blog.